Nick James

Guests included @prof-nick-james.bsky.social, Professor Ros Eeles, Dr Masood Moghul and Liz Bancroft, from the ICR and The Royal Marsden, who are doing pioneering work in #ProstateCancer.

The ICR was honoured to be represented for the impact of our research and our commitment to defeating cancer ❤️

NIHR Impact Prizes winner graphic for "The STAMPEDE trial at University College London, Christie Hospital Manchester and University of Manchester, Royal Marsden Hospital and Institute of Cancer Research, Leeds Teaching Hospital, Oncology Institute of Southern Switzerland"

Congratulations to @prof-nick-james.bsky.social and the STAMPEDE clinical trial team @mrcctu.bsky.social on this prestigious @nihr.bsky.social award! 👏🥳

STAMPEDE has made such a huge difference to #ProstateCancer treatment around the world.

#NIHRImpactPrizes

Thanks to @prof-nick-james.bsky.social from @icr.ac.uk‬ who accepted the award on behalf of the STAMPEDE team at the MRC CTU at UCL, site staff from more than 100 hospitals, and of course the 12,000 STAMPEDE participants.🏆

🎉Congratulations to @prof-nick-james.bsky.social and the STAMPEDE team on being shortlisted for @nihr.bsky.social's Impact Prizes for their work, over 20 years, on the trial assessing 10 different treatments in 12,000 men with advanced #ProstateCancer.

Good luck from everyone at the ICR! 🏆

Episode 14: Oncolytic Viruses & Clinical Trials: Expert Insights with Professor Kevin Harrington Trials and Tribulations | Oncology Trials Podcast · Episode

Latest Trials and Tribulations episode - injectables and replication competent viruses in trials with Prof Kevin Harrington open.spotify.com/episode/27Wt...

Thanks. Reposted now

Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer This randomized clinical trial explores whether hormone intensification at start of androgen deprivation therapy alters selection of androgen receptor (AR) gene alterations within the gene body and/or...

Latest from #STAMPEDE - intensified AR targeting drives increased prevalence of AR mutations at progression compared to monotherapy patient samples jamanetwork.com/journals/jam...

Amazing post-#APCCCDiagnostics25 ⛷️🚠🏂❄️🍴in Davos 🇨🇭
The best company in an enchanting location 🏔️
@silkegillessen.bsky.social @prof-nick-james.bsky.social @attardlab.bsky.social @aureliusomlin.bsky.social @apccc.bsky.social

Missed out on #GU25?

Listen to our latest podcast, and to a preview below, where
@prof-nick-james.bsky.social discusses updates from the STAMPEDE trial, and the benefits of transdermal estradiol patches in #prostatecancer!

#kcsm #uroonc #blcsm #pcsm @icr.ac.uk @ascocancer.bsky.social

Donate to Tour de 4: Sir Chris Hoy's - Zwift Rides, organized by Zwift Rides The Tour de 4 is an initiative launched by Sir Chris Hoy to change the perception… Zwift Rides needs your support for Tour de 4: Sir Chris Hoy's - Zwift Rides

Just completed the inspirational Chris Hoy’s inaugural Tour de 4 Zwift fundraiser for prostate cancer. Donate now! gofundme.com/f/tourde4-zwift

Episode 13: Breast Cancer Radiotherapy Trials featuring Dr Anna Kirby Trials and Tribulations | Oncology Trials Podcast · Episode

Latest episode of our podcast and our first foray into breast cancer. We talk to inspirational ESTRO President Anna Kirby about trial design and especially endpoints. Have a listen! @icrlondon.bsky.social open.spotify.com/episode/3ZLK...

Bladder cancer: MRI scanning and biopsy as shortcut to correct treatment BladderPath trial found that patients with suspected invasive bladder cancer undergoing initial mpMRI were treated faster than those assessed with TURBT alone

Patients with a common aggressive type of #bladdercancer could get correct treatment significantly quicker: new research led by @Prof-Nick-James.bsky.social and Professor Rik Bryan from 🇬🇧 @unibirmingham.bsky.social suggests that initial #MRI imaging and biopsy could reduce the wait times.

NXP800 activates the unfolded protein response, altering AR and E2F function to impact castration-resistant prostate cancer growth Abstract. Purpose: Advanced prostate cancer (PCa) is invariably fatal with the androgen receptor (AR) being a major therapeutic target. AR signaling inhibitors have improved overall survival for men w...

Important paper on targeting AR resistance by my @icrlondon.bsky.social colleague Adam Sharp aacrjournals.org/clincancerre...

📢 New episode out now! Involve Your Urologist! Prof Declan Murphy from @gu-onc.bsky.social discusses challenges facing surgical trials with @prof-nick-james.bsky.social @hoda-aty.bsky.social @mrcctu.bsky.social @icrlondon.bsky.social

open.spotify.com/show/643ey66...

Episode 12: Involve Your Urologist! Challenges facing surgical trials featuring Professor Declan Murphy Trials and Tribulations | Oncology Trials Podcast · Episode

Latest edition of our Trials and Tribulations now out featuring @gu-cast.bsky.social Declan Murphy on the role of urologists in trial design and conduct. open.spotify.com/episode/2SKX...

Delighted to receive the second edition pre prints of my Very Short Introduction to Cancer. Available in all good book shops from January !

So sad to hear about @felixfengmd passing away. A true giant of oncology but also the loveliest man you could ever hope to meet. A joy both to work with and to be with. His premature death a massive loss to humanity and a stark reminder why we do what we do. Rest in Peace 😢

Latest edition of our Trials and Tribulations podcast out now. We interview Renu Eapen about trials, surgical training and lab work all at the same time! x.com/trialstribsp...

#Movember

The Man Van🚐 by @royalmarsdenNHS and @ICR_London is making early #ProstateCancer detection accessible for men in underserved communities. This new study by @MMoghul et al. shows how it is a game changer in healthcare access

🔓➡️ doi.org/10.1002/ijc.35…

📰BREAKING: The Man Van can diagnose #ProstateCancer in at-risk groups earlier and more affordably than the GP route.

Find out more about the research into the mobile health clinic, presented at #LGCW2024 ⤵️

www.icr.ac.uk/news-archive...